The Journal of Allergy and Clinical Immunology
Volume 119, Issue 3 , Pages 731-738 , March 2007

Pediatric patients with eosinophilic esophagitis: An 8-year follow-up

  • Amal H. Assa'ad, MD

      Affiliations

    • From the Division of Allergy and Immunology
    • Corresponding Author InformationReprint requests: Amal H. Assa'ad, MD, Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, MLC 2000, Cincinnati, OH 45229.
    • ,
  • Philip E. Putnam, MD

      Affiliations

    • Division of Gastroenterology, Hepatology and Nutrition
    • ,
  • Margaret H. Collins, MD

      Affiliations

    • Division of Pathology
    • ,
  • Rachel M. Akers, MPH

      Affiliations

    • Division of Epidemiology and Biostatistics, Cincinnati Children's Hospital Medical Center
    • ,
  • Sean C. Jameson

      Affiliations

    • From the Division of Allergy and Immunology
    • ,
  • Cassie L. Kirby

      Affiliations

    • From the Division of Allergy and Immunology
    • ,
  • Bridget K. Buckmeier

      Affiliations

    • From the Division of Allergy and Immunology
    • ,
  • Jennifer Z. Bullock, MD

      Affiliations

    • From the Division of Allergy and Immunology
    • ,
  • Ann R. Collier, MD

      Affiliations

    • From the Division of Allergy and Immunology
    • ,
  • Michael R. Konikoff, MD

      Affiliations

    • Division of Gastroenterology, Hepatology and Nutrition
    • ,
  • Richard J. Noel, MD, PhD

      Affiliations

    • Division of Gastroenterology and Nutrition, Medical College of Wisconsin and Children's Hospital of Wisconsin
    • ,
  • Jesus R. Guajardo, MD, MHPE

      Affiliations

    • Pulmonary/Allergy, Child Health, University of Missouri
    • ,
  • Marc E. Rothenberg, MD, PhD

      Affiliations

    • From the Division of Allergy and Immunology

Received 13 June 2006 ,Revised 13 October 2006 ,Accepted 23 October 2006.

  • Image Result

    Age distribution, at the time of diagnosis of EE, of 89 patients.

    Age distribution, at the time of diagnosis of EE, of 89 patients.

  • Image Result

    Most commonly encountered combinations of histopathology in segments of the gastrointestinal tract in pediatric subjects with eosinophilic esophagitis. Although all subjects had eosinophilia of the es

    Most commonly encountered combinations of histopathology in segments of the gastrointestinal tract in pediatric subjects with eosinophilic esophagitis. Although all subjects had eosinophilia of the esophagus (black and red bars), a minority had pathology confined just to the esophagus (first group from the bottom). In the rest of the subjects, the distribution of eosinophilic and noneosinophilic inflammation of other gastrointestinal segments varied. The group second from the bottom of the graph had additional pathology in the stomach and duodenum (green and yellow bars). In the next group, the pathology skipped the stomach but involved the duodenum. The fourth group had pathology in all segments of the gastrointestinal. The top 2 groups had, in addition to the esophagus, pathology of the stomach only or the colon only (blue bar).

  • Image Result
    Diagram of patients enrolled in the study, number of upper endoscopies, duration of follow-up, and outcome at the end of the follow-up period.

    Diagram of patients enrolled in the study, number of upper endoscopies, duration of follow-up, and outcome at the end of the follow-up period.

 Supported by a 2005 American Academy of Allergy, Asthma & Immunology/Sanofi Aventis Women Physicians in Allergy Project Grant Award (A.H.A.) and a 2004 American Academy of Allergy, Asthma & Immunology Clinical Fellowship Award (J.Z.B.).Disclosure of potential conflict of interest: A. H. Assa'ad has consulting arrangements with and has received grant support from GlaxoSmithKline. M. H. Collins has consulting arrangements with GlaxoSmithKline and Ception Therapeutics. R. J. Noel has consulting arrangements with Ception Therapeutics. M. E. Rothenberg has consulting arrangements with GlaxoSmithKline, Ception Therapeutics, Cambridge Antibody Technology, Tanox, and MedaCorp; owns stock in Ception Therapeutics; has received grant support from Cambridge Antibody Technology; and is on the speakers' bureau for Merck. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(06)03792-4

doi: 10.1016/j.jaci.2006.10.044

The Journal of Allergy and Clinical Immunology
Volume 119, Issue 3 , Pages 731-738 , March 2007

Article Tools

* Image Usage & Resolution